TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from AnaptysBio ( (ANAB) ).
On November 20, 2025, AnaptysBio filed a Verified Complaint against TESARO, Inc. in Delaware Chancery Court, alleging breach of their Collaboration and Exclusive License Agreement and tortious interference by GlaxoSmithKline, TESARO’s parent company. AnaptysBio claims TESARO violated exclusivity obligations by engaging in clinical trials with competing PD-1 antagonists and failed to maximize commercial returns for Jemperli. Previously, in 2020, AnaptysBio filed a similar complaint against GSK, resulting in a settlement with increased royalties. Despite attempts at resolution, TESARO counter-sued AnaptysBio, seeking injunctive relief. An expedited trial is set for July 2026, with ongoing milestone and royalty payments to AnaptysBio.
The most recent analyst rating on (ANAB) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.
Spark’s Take on ANAB Stock
According to Spark, TipRanks’ AI Analyst, ANAB is a Neutral.
AnaptysBio’s overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and a precarious balance sheet. While technical indicators show positive momentum, the negative valuation metrics due to ongoing losses further weigh down the score.
To see Spark’s full report on ANAB stock, click here.
More about AnaptysBio
AnaptysBio, Inc. operates in the biotechnology industry, focusing on the development of therapeutic antibodies for the treatment of various diseases. The company is known for its work in immuno-oncology and inflammation, with a market focus on developing innovative therapies for unmet medical needs.
Average Trading Volume: 580,403
Technical Sentiment Signal: Buy
Current Market Cap: $1.02B
Find detailed analytics on ANAB stock on TipRanks’ Stock Analysis page.